RxDoctor Payments Data

Kera Steward

Family · Corpus Christi, TXNPI 1265093918

Payments from drug & device makers

$849in general payments, 2019–2025

Across 27 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$190
  • Novo Nordisk$161
  • Medtronic$117
  • AbbVie$85
  • Inspire Medical Systems, Inc.$80
  • Pfizer$55
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$9,460
Medicare patients
44
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$77,087
OzempicSemaglutide39$42,359
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$14,843
EliquisApixaban16$11,700
Novolog FlexpenInsulin Aspart17$4,033
SymbicortBudesonide/Formoterol Fumarate13$3,756
Wixela InhubFluticasone Propion/Salmeterol20$2,326
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,972
Levothyroxine Sodium149$1,570
Omeprazole86$1,474
Atorvastatin Calcium158$1,317
Gabapentin68$1,305
Albuterol Sulfate HfaAlbuterol Sulfate42$1,232
Venlafaxine Hcl ErVenlafaxine Hcl31$1,153
SynthroidLevothyroxine Sodium17$1,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$190$77,08761 claims
Novo NordiskOzempic$161$42,35939 claims
PfizerEliquis$55$11,70016 claims
AstraZenecaSymbicort$13$3,75613 claims
AbbVieSynthroid$85$1,03817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →